Patient and transplant characteristics
| . | De novo AML (n = 590) . | sAML (n = 129) . | P . | Overall (N = 719) . |
|---|---|---|---|---|
| Follow-up (mo), median [IQR] | 43.48 [37.53-47.99] | 45.59 [39.08-57.85] | .20 | 43.48 [39.47-47.69] |
| Patient age (y), median (min-max) [IQR] | 55.4 (18-77.8) [42.6-63] | 61.3 (21-78.8) [55-67.3] | <.0001 | 57.2 (18-78.8) [44.2-63.8] |
| Patient sex | 339 (57.6%) | 84 (65.1%) | .11 | 423 (58.9%) |
| Male | 250 (42.4%) | 45 (34.9%) | 295 (41.1%) | |
| Female | 1 | 0 | 1 | |
| Year of transplant, median (min-max) | 2017 (2010-2022) | 2018 (2010-2022) | .62 | 2017 (2010-2022) |
| Cytogenetic risk group | ||||
| Favorable | 28 (5.9%) | 4 (4%) | .75 | 32 (5.6%) |
| Intermediate | 282 (59.4%) | 58 (58.6%) | 340 (59.2%) | |
| Adverse | 165 (34.7%) | 37 (37.4%) | 202 (35.2%) | |
| Missing | 115 | 30 | 145 | |
| Status at transplant | ||||
| PR | 346 (58.6%) | 95 (73.6%) | .002 | 441 (61.3%) |
| First relapse | 244 (41.4%) | 34 (26.4%) | 278 (38.7%) | |
| Donor age (y) | ||||
| Median (min-max) [IQR] | 38.3 (13-73.9) [29.4-48] | 36.9 (16.6-64) [29.1-43.9] | .21 | 38.2 (13-73.9) [29.3-47.1] |
| Missing | 20 | 3 | 23 | |
| Donor sex | ||||
| Donor male | 365 (62.1%) | 81 (62.8%) | .88 | 446 (62.2%) |
| Donor female | 223 (37.9%) | 48 (37.2%) | 271 (37.8%) | |
| Missing | 2 | 0 | 2 | |
| Female-to-male combination | ||||
| No F→M | 466 (79.1%) | 102 (79.1%) | .99 | 568 (79.1%) |
| F→M | 123 (20.9%) | 27 (20.9%) | 150 (20.9%) | |
| Missing | 1 | 0 | 1 | |
| Conditioning intensity | ||||
| MAC | 281 (47.8%) | 51 (39.8%) | .10 | 332 (46.4%) |
| RIC | 307 (52.2%) | 77 (60.2%) | 384 (53.6%) | |
| Missing | 2 | 1 | 3 | |
| Cell source | ||||
| BM | 196 (33.2%) | 39 (30.2%) | .51 | 235 (32.7%) |
| PB | 394 (66.8%) | 90 (69.8%) | 484 (67.3%) | |
| KPS | ||||
| <90 | 249 (44.1%) | 64 (50.8%) | .17 | 313 (45.3%) |
| ≥90 | 316 (55.9%) | 62 (49.2%) | 378 (54.7%) | |
| Missing | 25 | 3 | 28 | |
| HCT-CI | ||||
| HCT-CI, 0-2 | 422 (78.1%) | 74 (59.7%) | <.0001 | 496 (74.7%) |
| HCT-CI, ≥3 | 118 (21.9%) | 50 (40.3%) | 168 (25.3%) | |
| Missing | 50 | 5 | 55 | |
| Patient CMV | ||||
| Negative | 143 (24.6%) | 26 (20.2%) | .29 | 169 (23.8%) |
| Positive | 439 (75.4%) | 103 (79.8%) | 542 (76.2%) | |
| Missing | 8 | 0 | 8 | |
| Donor CMV | ||||
| Negative | 233 (40.7%) | 60 (46.9%) | .2 | 293 (41.8%) |
| Positive | 340 (59.3%) | 68 (53.1%) | 408 (58.2%) | |
| Missing | 17 | 1 | 18 | |
| TBI | ||||
| CT | 484 (82.2%) | 105 (81.4%) | .83 | 589 (82%) |
| TBI | 105 (17.8%) | 24 (18.6%) | 129 (18%) | |
| Missing | 1 | 0 | 1 |
| . | De novo AML (n = 590) . | sAML (n = 129) . | P . | Overall (N = 719) . |
|---|---|---|---|---|
| Follow-up (mo), median [IQR] | 43.48 [37.53-47.99] | 45.59 [39.08-57.85] | .20 | 43.48 [39.47-47.69] |
| Patient age (y), median (min-max) [IQR] | 55.4 (18-77.8) [42.6-63] | 61.3 (21-78.8) [55-67.3] | <.0001 | 57.2 (18-78.8) [44.2-63.8] |
| Patient sex | 339 (57.6%) | 84 (65.1%) | .11 | 423 (58.9%) |
| Male | 250 (42.4%) | 45 (34.9%) | 295 (41.1%) | |
| Female | 1 | 0 | 1 | |
| Year of transplant, median (min-max) | 2017 (2010-2022) | 2018 (2010-2022) | .62 | 2017 (2010-2022) |
| Cytogenetic risk group | ||||
| Favorable | 28 (5.9%) | 4 (4%) | .75 | 32 (5.6%) |
| Intermediate | 282 (59.4%) | 58 (58.6%) | 340 (59.2%) | |
| Adverse | 165 (34.7%) | 37 (37.4%) | 202 (35.2%) | |
| Missing | 115 | 30 | 145 | |
| Status at transplant | ||||
| PR | 346 (58.6%) | 95 (73.6%) | .002 | 441 (61.3%) |
| First relapse | 244 (41.4%) | 34 (26.4%) | 278 (38.7%) | |
| Donor age (y) | ||||
| Median (min-max) [IQR] | 38.3 (13-73.9) [29.4-48] | 36.9 (16.6-64) [29.1-43.9] | .21 | 38.2 (13-73.9) [29.3-47.1] |
| Missing | 20 | 3 | 23 | |
| Donor sex | ||||
| Donor male | 365 (62.1%) | 81 (62.8%) | .88 | 446 (62.2%) |
| Donor female | 223 (37.9%) | 48 (37.2%) | 271 (37.8%) | |
| Missing | 2 | 0 | 2 | |
| Female-to-male combination | ||||
| No F→M | 466 (79.1%) | 102 (79.1%) | .99 | 568 (79.1%) |
| F→M | 123 (20.9%) | 27 (20.9%) | 150 (20.9%) | |
| Missing | 1 | 0 | 1 | |
| Conditioning intensity | ||||
| MAC | 281 (47.8%) | 51 (39.8%) | .10 | 332 (46.4%) |
| RIC | 307 (52.2%) | 77 (60.2%) | 384 (53.6%) | |
| Missing | 2 | 1 | 3 | |
| Cell source | ||||
| BM | 196 (33.2%) | 39 (30.2%) | .51 | 235 (32.7%) |
| PB | 394 (66.8%) | 90 (69.8%) | 484 (67.3%) | |
| KPS | ||||
| <90 | 249 (44.1%) | 64 (50.8%) | .17 | 313 (45.3%) |
| ≥90 | 316 (55.9%) | 62 (49.2%) | 378 (54.7%) | |
| Missing | 25 | 3 | 28 | |
| HCT-CI | ||||
| HCT-CI, 0-2 | 422 (78.1%) | 74 (59.7%) | <.0001 | 496 (74.7%) |
| HCT-CI, ≥3 | 118 (21.9%) | 50 (40.3%) | 168 (25.3%) | |
| Missing | 50 | 5 | 55 | |
| Patient CMV | ||||
| Negative | 143 (24.6%) | 26 (20.2%) | .29 | 169 (23.8%) |
| Positive | 439 (75.4%) | 103 (79.8%) | 542 (76.2%) | |
| Missing | 8 | 0 | 8 | |
| Donor CMV | ||||
| Negative | 233 (40.7%) | 60 (46.9%) | .2 | 293 (41.8%) |
| Positive | 340 (59.3%) | 68 (53.1%) | 408 (58.2%) | |
| Missing | 17 | 1 | 18 | |
| TBI | ||||
| CT | 484 (82.2%) | 105 (81.4%) | .83 | 589 (82%) |
| TBI | 105 (17.8%) | 24 (18.6%) | 129 (18%) | |
| Missing | 1 | 0 | 1 |
BM, bone marrow; CT, chemotherapy; F, female; M, male; max, maximum; min, minimum; PB, peripheral blood; RIC, reduced intensity conditioning.